The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
BonadonnaG., ZucaliR., DeLenaM.Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Cancer Treat Rep.1977; 61: 769–77.
2.
CanellosG.P., AndersonJ.R., PropertK.J.Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med.1992; 327: 1478–84.
3.
HarkerW.G., KushlanP., RosenbergS.A.Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med.1984; 101: 440–6.
4.
KrikorianJ.G., PortlockC.S., RosenbergS.A.Treatment of advanced Hodgkin's disease with Adriamycin, bleomycin, vinblas-tine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer.1978; 41: 2107–11.
5.
SantoroA., BonadonnaG., ValagussaP.Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol.1987; 5: 27–37.
6.
BonadonnaG., ZucaliR., MonfardiniS.Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide vs MOPP. Cancer.1975; 36: 252–9.
7.
GlickJ.H., YoungM.L., HarringtonD.MOPP/ABVD hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial. J Clin Oncol.1998; 16: 19–26.
8.
SomersR., CardeP., Henry-AmarM.A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP and ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Piere-et-Marie-Curie controlled clinical trial. J Clin Oncol.1994; 12: 279–87.
9.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–9.
10.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56(8): 729–64.
11.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11(11A): 57–89.
12.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
SolimandoD., WilsonJ.Doxorubicin-induced hypersensitivity reactions. Drug Intell and Clin Pharmacy.1984; 18(10): 808–11.
15.
American Society of Clinical Oncology.Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.1994; 12(11): 2471–508.
16.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18:3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
19.
SilvestriF., FaninF.R., VelisigM.The role of granulocyte colony-stimulating factor (filgrastim) in maitaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's Disease. Tumori.1994; 80: 453–8.
20.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–9.
21.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–405.
22.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
23.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: PerryM.C., ed. The Chemotherapy Source Book.2nd ed.Baltimore, MD: Williams and Wilkins; 1996, 727–44.
24.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
25.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24(4): 969–90.
